Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753021 | 0.74 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2A | |
| SCHEMBL25160320 | 0.73 | KDM4E (0.38) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL13793446 | 0.71 | TSHR (0.39) | KDM4EGAAALDH1A1MEN1KMT2A | |
| SCHEMBL24856128 | 0.70 | TSHR (0.41) | CYP1A2CYP2D6KDM4EGAAALDH1A1 | |
| SCHEMBL13793645 | 0.69 | KDM4E (0.42) | KDM4EGAAALDH1A1 | |
| SCHEMBL8183109 | 0.67 | S1PR2 (0.50) | GAAALDH1A1 | |
| SCHEMBL20724268 | 0.66 | MAPT (0.32) | ALDH1A1 | |
| SCHEMBL27368808 | 0.66 | GAA (0.40) | GAAMEN1KMT2ALMNA | |
| SCHEMBL20234596 | 0.65 | DPP4 (0.37) | KDM4EGAA | |
| SCHEMBL31631394 | 0.65 | PRMT1 (0.50) | ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | CYP1A2 3971/4885CYP3A4 2201/4885CYP2D6 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.